Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update.
about
Heparin-induced thrombocytopenia in the ICU: an overviewUnfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patientsVenous thromboembolic diseaseBilateral adrenal hemorrhage: the unrecognized cause of hemodynamic collapse associated with heparin-induced thrombocytopenia.Heparin-induced thrombocytopenia: treatment options and special considerations.High prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin-induced thrombocytopenia.Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia.Incidence of antiheparin-platelet factor 4 antibodies and heparin-induced thrombocytopenia in Turkish patients undergoing cardiac surgery.Heparin-induced thrombocytopenia and recent advances in its therapy.Current concepts review: heparin-induced thrombocytopenia.Heparin induced thrombocytopenia and re-thrombosis associated with warfarin and fondaparinux in a childEvaluation of a clinical scoring scale to direct early appropriate therapy in heparin-induced thrombocytopenia.The use of danaparoid to manage coagulopathy in a neurosurgical patient with heparin-induced thrombocytopenia type II and intracerebral haemorrhage.Cerebral venous thrombosis due to essential thrombocythemia and worsened by heparin-induced thrombocytopenia and thrombosis.Utility of ELISA optical density values and clinical scores for the diagnosis of and thrombosis prediction in heparin-induced thrombocytopenia.The direct medical costs associated with suspected heparin-induced thrombocytopenia.Evaluation of two new automated chemiluminescent assays (HemosIL® AcuStar HIT-IgG and HemosIL® AcuStar HIT-Ab) for the detection of heparin-induced antibodies in the diagnosis of heparin-induced thrombocytopenia.Clinical experience with argatroban for heparin-induced thrombocytopenia in a large teaching hospital.Usefulness of anti-PF4/heparin antibody test for intensive care unit patients with thrombocytopenia.Heparin-induced thrombocytopenia (HIT II) in liver transplant recipients: a retrospective multivariate analysis of prognostic factors.The Pharmacotherapy of Heparin-Induced Thrombocytopenia (HIT) : A Review of Contemporary Therapeutic Challenges in Clinical Practice.Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia.A systematic review of the quality of economic models comparing thrombosis inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention.Impact of Platelet Functional Assays on the Cost of Treating Suspected Heparin-Induced Thrombocytopenia.Repeated early hemofiltration filters clotting and heparin-induced thrombocytopenia in ICU.Safety and economic considerations of argatroban use in critically ill patients: a retrospective analysisComparisons of argatroban to lepirudin and bivalirudin in the treatment of heparin-induced thrombocytopenia: a systematic review and meta-analysis.Cerebral venous sinus thrombosis risk factors.Emerging drugs for acute myocardial infarction.Enoxaparin: a pharmacologic and clinical review.A rapid test (STic Expert® ) for the diagnosis of heparin-induced thrombocytopenia.Platelet recruitment to venous stent thrombi.
P2860
Q21194907-88CBE888-FBF5-4592-98D6-80DBECF0CD65Q24241979-180FEC75-6AF0-446E-9A1D-CB668EA14173Q24631121-FC9BC361-639C-4D74-82DC-497BB133EE6DQ30427572-FD44BF79-B709-44F8-B3B7-FEF9FFCE3897Q33374658-C6EF104A-24D0-4D1C-9F89-621FE4B3D598Q33374739-7DDF1C87-CCF9-4D26-9EAC-58B7E74A89BDQ33375376-405360B5-6964-461E-A6BF-DF1FD8504CF8Q33375919-32EDC3D9-F88C-4D15-9706-73632A062A1FQ33377436-355B218D-D45D-433A-9B68-F6330126A0A2Q33382108-C9646039-6B73-4E9F-853D-693C2C6B228AQ33384369-B1EABA67-7357-4CD1-B3AD-F79F7B27D900Q33385898-92978F4C-46DB-4F07-BB03-BBCFE9D7C5A6Q33391391-2E3FF54F-702F-4F7C-A5B5-2BF9CF22CBE8Q33393189-B1EB11A9-9905-4D47-B136-A5249C202A5CQ33393683-0DC6B53C-CD50-4152-AE90-A02535AAECA9Q33394835-A9F7EF0E-BB4A-418F-A374-39EF98A1D5DDQ33400181-AA1F493A-8DC8-4515-B748-C085B1620BB5Q33400597-77AE79EB-0753-4AEB-B72D-C61BE80DE5C9Q33400605-F73C0141-33F4-46C6-9604-814C8F462F3CQ33401025-EB32CEEF-AE5F-4A09-8C9F-03AA4D7B02F0Q33401236-C7726424-25B6-40EB-A2A0-FD5BEEF61C2AQ33407198-C70DF36F-C801-4FA8-9152-AEF907616D8AQ33413196-9CD1F7DA-8EB1-40F4-815A-25745A22AA66Q33413359-CAD8B4F9-E2CC-4D90-836B-26D902D2E747Q33415852-C4CB375B-7762-4CDF-B621-F308E05720D8Q33422064-A3499EFB-AF2A-45AE-9D98-EFCD733A6C1AQ33442600-1BAF5EDE-8F88-4694-B77E-BF4DB9B86B9AQ37453642-33A7294E-E529-4370-98F6-9843415694F4Q37670190-D946470F-2B3E-4AE6-AA41-6D7C840E07DBQ37862264-0BCC89E5-5F9A-4EA5-87DE-787F94DA2447Q49139435-FC226656-094A-4E48-AED8-EDAB224B76DAQ51063246-7ACBA59C-9BB9-4410-BB99-E09ABDC5B2BC
P2860
Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Recognition, treatment, and pr ...... ocytopenia: review and update.
@ast
Recognition, treatment, and pr ...... ocytopenia: review and update.
@en
type
label
Recognition, treatment, and pr ...... ocytopenia: review and update.
@ast
Recognition, treatment, and pr ...... ocytopenia: review and update.
@en
prefLabel
Recognition, treatment, and pr ...... ocytopenia: review and update.
@ast
Recognition, treatment, and pr ...... ocytopenia: review and update.
@en
P1433
P1476
Recognition, treatment, and pr ...... ocytopenia: review and update.
@en
P304
P356
10.1016/J.THROMRES.2005.07.012
P577
2005-09-01T00:00:00Z